Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ATYR
ATYR logo

ATYR Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy aTyr Pharma Inc (ATYR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
0.500
1 Day change
-10.00%
52 Week Range
7.290
Analysis Updated At
2026/05/15
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

ATYR is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading below key moving averages with weak momentum, no supporting news catalyst, no strong proprietary buy signal, and no recent institutional, insider, or congress buying support. The current setup favors avoiding entry and waiting for a clearer trend improvement.

Technical Analysis

Technicals are bearish. MACD histogram is -0.0394 and still expanding lower, which signals weakening momentum. RSI_6 at 36.29 is neutral-to-weak and not oversold enough to imply a strong rebound. The moving average structure is bearish with SMA_200 > SMA_20 > SMA_5, showing the stock is in a downtrend. Current price around 0.56 is below the pivot at 0.744 and still above S1 at 0.494, so the stock is closer to support than breakout territory, but the trend remains negative. The short-term pattern model suggests only modest upside probabilities, not enough to justify a confident long-term buy.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is strongly bullish on paper because call open interest and call volume greatly exceed puts. However, the contract activity is likely speculative given the very low share price and extremely high implied volatility (260.27) and historical volatility (208.97). Option volume today is elevated versus its 30-day average, which suggests attention is present, but this does not outweigh the weak technical trend.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
9
Buy
4

Positive Catalysts

  • ["Options flow is heavily call-skewed with open interest put-call ratio at 0.07 and volume put-call ratio at 0.05.", "Recent option volume is above the 30-day average, indicating active trading interest.", "Stock trend model shows a mild positive short-term bias, with estimated upside over the next day, week, and month.", "Current price is closer to support than resistance, which could allow a bounce if buyers step in."]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no fresh catalyst driving the stock.", "AI Stock Picker: no signal on given stock today.", "SwingMax: no signal on given stock recently.", "Insiders are neutral with no meaningful buying activity over the last month.", "Hedge funds are neutral with no significant trading trends over the last quarter.", "No recent congress trading data is available.", "Technical trend is bearish with MACD negative and moving averages stacked bearishly.", "Financial snapshot data was unavailable, so there is no evidence of recent fundamental improvement."]

Financial Performance

Latest quarter season could not be assessed because the financial snapshot data returned an error and no quarterly revenue or earnings figures were provided. As a result, there is no usable latest-quarter growth readout to support a long-term buy thesis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided, so there is no evidence of improving Wall Street conviction. Given the lack of analyst upgrades, the neutral hedge fund/insider backdrop, and weak technicals, Wall Street pros appear unconvinced at this time.

Wall Street analysts forecast ATYR stock price to rise
2 Analyst Rating
Wall Street analysts forecast ATYR stock price to rise
0 Buy
2 Hold
0 Sell
Hold
Current: 0.560
sliders
Low
1
Averages
1
High
1
Current: 0.560
sliders
Low
1
Averages
1
High
1
Leerink
Faisal Khurshid
Outperform
maintain
$NULL
AI Analysis
2025-09-15
Reason
Leerink
Faisal Khurshid
Price Target
$NULL
AI Analysis
2025-09-15
maintain
Outperform
Reason
Leerink analyst Faisal Khurshid keeps an Outperform rating on aTyr Pharma after the company said the Phase 3 EFZO-FIT trial of efzofitimod in pulmonary sarcoidosis failed to meet its primary endpoint of steroid reduction. While aTyr plans to engage with the FDA on a potential path forward, Leerink's expectations are low given the primary endpoint miss and unclear relevance of KSQ-Lung score improvements alone, the analyst tells investors in a research note. Going into the readout, the firm expected a primary endpoint miss would see 80%-90% share downside. aTyr Pharma shares are down 82%, or $4.97, to $1.07 in early trading.
Cantor Fitzgerald
Overweight -> Neutral
downgrade
2025-09-15
Reason
Cantor Fitzgerald
Price Target
2025-09-15
downgrade
Overweight -> Neutral
Reason
Cantor Fitzgerald downgraded aTyr Pharma to Neutral from Overweight after the company announced that the Phase 3 pulmonary sarcoidosis trial for efzofitimod missed the primary endpoint of change in mean steroid dose from baseline at week 48. aTyr plans to engage with the FDA to determine the path forward, but the firm doesn't have much confidence in the path forward for efzo in pulmonary sarcoidosis, the analyst tells investors.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ATYR
Unlock Now

People Also Watch